NOTE 8 - STOCK BASED COMPENSATION |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NOTE 8 - STOCK BASED COMPENSATION | NOTE 8 - STOCK BASED COMPENSATION
Effective July 15, 2024, the Company adopted the “AIBiotics, Inc.” limits the number of shares that may be issued pursuant to the 2024 Plan to 50,000,000 shares of common stock. As of June 30, 2026, there have not been any stock-based compensation issuances under the 2024 Plan.
On January 13, 2026, the Company’s Board of Directors approved the adoption of the 2026 Equity Incentive Plan (the “Plan”), subject to stockholder approval. The Plan provides for the issuance of up to 500,000,000 shares of common stock for equity-based awards, including stock options, restricted stock, restricted stock units, and other equity or cash-based incentives, to employees, directors, consultants, and other service providers. The Plan is intended to align employee and shareholder interests and to support long-term growth and retention. As of June 30, 2026, there have not been any stock-based compensation issuances under the 2026 Plan.
Warrants Issued
The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the six months ended June 30, 2026, and 2025:
The intrinsic value of warrants outstanding as of June 30, 2026 was $0. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||